State residents would have an opportunity to vote on the initiative in the general election in Nov. 2014.
The Alzheimer’s Research Bond Act of 2014 would fund scientific research of Alzheimer’s disease, including tracking its causes, treatment and clinical trails of medication. By issuing taxpayers approved bonds for Alzheimer’s research, the state of New York can leverage new revenues to provide research grants and other financing to collaborations of New York institutions while also creating jobs and leading the effort to find a cure.
“The reality is that the cost of treating Alzheimer’s in the United States is expected to increase from $203 billion in 2013 to $1.2 trillion by 2050,” said Lavine. “Exploring treatment and cures for the disease is uniquely challenging, especially in the light of recent research that indicates the onset of Alzheimer’s begins long before a diagnosis. At a time when federal investments in research for the disease are at an all-time low, there needs to be a dedicated funding stream for ongoing studies."
Lavine initially unveiled his ideal at a press conference with Rep. Steve Israel, D-Huntington, at the Cold Spring Harbor Laboratory. Hiro Furukawa, Associate Professor and researcher at CSHL, said at the time that the availability of funding is vital to a robust research program.
The Long Island Chapter of
the Alzheimer’s Association, cites Alzheimer’s as the sixth leading cause of
death in the U.S. and the only disease in which there is no way to prevent,
cure or slow its progressions. It is estimated the 300,000 plus New York State
residents have Alzheimer’s, dementia and other related diseases.